CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands |
Series D Preferred Stock [Member]
Common Stock [Member]
At-the-Market Offering [Member]
|
Series D Preferred Stock [Member]
Common Stock [Member]
Settlement of Preferred Stock [Member]
|
Series D Preferred Stock [Member]
Common Stock [Member]
Cashless Exercise of Warrants [Member]
|
Series D Preferred Stock [Member]
Common Stock [Member]
Exercise of Options [Member]
|
Series D Preferred Stock [Member]
Common Stock [Member]
Exercise of Warrants [Member]
|
Series D Preferred Stock [Member]
Common Stock [Member]
|
Series E Preferred Stock [Member]
Additional Paid-in Capital [Member]
At-the-Market Offering [Member]
|
Series E Preferred Stock [Member]
Additional Paid-in Capital [Member]
Settlement of Preferred Stock [Member]
|
Series E Preferred Stock [Member]
Additional Paid-in Capital [Member]
Exercise of Options [Member]
|
Series E Preferred Stock [Member]
Additional Paid-in Capital [Member]
Exercise of Warrants [Member]
|
Series E Preferred Stock [Member]
Additional Paid-in Capital [Member]
Trek Therapeutics, PBC [Member]
|
Series E Preferred Stock [Member]
Additional Paid-in Capital [Member]
|
Series E Preferred Stock [Member]
Retained Earnings [Member]
|
Series C Preferred Stock [Member]
Settlement of Preferred Stock [Member]
|
Series C Preferred Stock [Member] |
Noncontrolling Interest [Member]
Trek Therapeutics, PBC [Member]
|
Noncontrolling Interest [Member] |
At-the-Market Offering [Member] |
Exercise of Options [Member] |
Exercise of Warrants [Member] |
Trek Therapeutics, PBC [Member] |
Total |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Balance at Dec. 31, 2019 | $ 23 | $ 115,910 | $ (104,787) | $ 515 | $ 11,661 | |||||||||||||||||
Balance (in Shares) at Dec. 31, 2019 | 23,323,087 | |||||||||||||||||||||
Sale of common stock | $ 5 | $ 2,228 | 25,210 | $ 2,228 | 25,215 | |||||||||||||||||
Sale of common stock (in Shares) | 424,357 | 4,687,500 | ||||||||||||||||||||
Sale of subsidiary shares to non-controlling interest | 7,124 | 3,468 | $ 10,592 | |||||||||||||||||||
Sale of subsidiary shares to non-controlling interest (in Shares) | 83,055 | |||||||||||||||||||||
Common stock issued for services | $ 1 | 4,399 | $ 4,400 | |||||||||||||||||||
Common stock issued for services (in Shares) | 679,555 | |||||||||||||||||||||
Fair value of subsidiary shares issued to acquire research and development | $ 2,439 | 1,051 | $ 735 | 248 | $ 3,174 | 1,299 | ||||||||||||||||
Stock based compensation | 17,983 | 2,782 | 20,765 | |||||||||||||||||||
Stock based compensation (in Shares) | 219,334 | |||||||||||||||||||||
Preferred Stock dividend | (14) | (14) | ||||||||||||||||||||
Net loss | (52,218) | (6,922) | $ (59,140) | |||||||||||||||||||
Common stock issued upon conversion of preferred stock and accrued dividends | $ 70 | 110 | $ 70 | $ 110 | ||||||||||||||||||
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares) | 15,516 | 29,334 | ||||||||||||||||||||
Common stock issued upon exercise of warrants | $ 1 | $ 2,089 | $ 2,090 | |||||||||||||||||||
Common stock issued upon exercise of warrants (in Shares) | 12,840 | 542,646 | ||||||||||||||||||||
Common stock issued in exchange for subsidiary shares | 24 | (24) | ||||||||||||||||||||
Common stock issued in exchange for subsidiary shares (in Shares) | 83,055 | 44,850 | ||||||||||||||||||||
Common stock issued upon exercise of options | $ 1 | $ 2,721 | $ 2,722 | |||||||||||||||||||
Common stock issued upon exercise of options (in Shares) | 586,825 | 160,743 | 1,203,223 | |||||||||||||||||||
Balance at Dec. 31, 2020 | $ 31 | 181,344 | (157,005) | 802 | $ 25,172 | |||||||||||||||||
Balance (in Shares) at Dec. 31, 2020 | 30,764,792 | 30,764,792 | ||||||||||||||||||||
Sale of common stock | $ 1,300 | $ 1,300 | ||||||||||||||||||||
Sale of common stock (in Shares) | 251,720 | |||||||||||||||||||||
Change in fair value of modified options | 313 | 8 | $ 321 | |||||||||||||||||||
Sale of subsidiary shares to non-controlling interest | $ 3 | 9,001 | 9,004 | |||||||||||||||||||
Sale of subsidiary shares to non-controlling interest (in Shares) | 2,500,000 | |||||||||||||||||||||
Common stock issued for services | $ 1 | 3,974 | 3,975 | |||||||||||||||||||
Common stock issued for services (in Shares) | 1,124,341 | |||||||||||||||||||||
Stock based compensation | $ 1 | 5,176 | 348 | 5,525 | ||||||||||||||||||
Stock based compensation (in Shares) | 916,952 | |||||||||||||||||||||
Preferred Stock dividend | (9) | (9) | ||||||||||||||||||||
Net loss | (31,917) | (939) | $ (32,856) | |||||||||||||||||||
Common stock issued upon conversion of preferred stock and accrued dividends | $ 28 | $ 28 | ||||||||||||||||||||
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares) | 9,375 | |||||||||||||||||||||
Common stock issued upon exercise of options (in Shares) | 9,375 | 9,375 | ||||||||||||||||||||
Balance at Dec. 31, 2021 | $ 36 | $ 201,127 | $ (188,922) | $ 219 | $ 12,460 | |||||||||||||||||
Balance (in Shares) at Dec. 31, 2021 | 35,567,180 | 35,567,180 |
X | ||||||||||
- Definition Value of common stock issued upon exercise of warrants. No definition available.
|
X | ||||||||||
- Definition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of expense or loss included in net income that result in no cash flow, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Number of shares issued during the period as a result of the conversion of convertible securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. No definition available.
|
X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of shares of stock issued attributable to transactions classified as other. No definition available.
|
X | ||||||||||
- Definition Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of share options (or share units) exercised during the current period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The gross value of stock issued during the period upon the conversion of convertible securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components. No definition available.
|
X | ||||||||||
- Definition Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. No definition available.
|
X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. No definition available.
|
X | ||||||||||
- Definition Value of stock issued as a result of the exercise of stock options. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy. No definition available.
|
X | ||||||||||
- Definition Number of increase (decrease) in shares of stock classified as other. No definition available.
|